CatalystMarker
Sign in
← board

GEHC

GE Healthcaredistress 3/10 · well-funded / low risk
$61.240%today-31% from 52w high
gehealthcare.com54,000 employeesFounded 2022Chicago, ILMedical Devices
Lead: Colorectal Cancer · est. market ~$12B (approx, global)
Revenue
$5131M
Liquidity
$2613M
Runway
—
Shares 1y
0%

Price & events

-25.2% over 6M
$59.49$71.86$84.23Jan 26Apr 26Jul 2623.5Mfinancing: 8-K material_agreement (2026-02-27)rating: Hovde Group: Market Perform (2026-07-17)rating: UBS: Neutral (2026-07-16)rating: BMO Capital: Market Perform (2026-07-09)rating: RBC Capital: Outperform (2026-06-23)rating: UBS: Sell → Neutral (2026-05-21)rating: Citigroup: Neutral (2026-04-30)rating: JP Morgan: Neutral (2026-04-30)rating: Goldman Sachs: Buy → Neutral (2026-04-30)
CatalystRating changeDilutionFinancingdashed = today
-0.3%
1D
-6.8%
1W
-3.9%
1M
-12.4%
3M
-23.2%
6M
-20.6%
1Y
-24.0%
2Y
—
5Y
+2.6%
All

Overview

Market Cap
$27.86B
Enterprise Value
$35.72B
Volume
213.02K
52 Week Range
$59.48 – $88.16
Total Shares
454.89M
Float Shares
453.43M
Short %
3.58%
% Held by Insiders
0.35%
% Held by Institutions
93.86%
RVOL
0.04x
Beta
0.84

Pipeline stages · 4 programs

Regadenoson
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2026-12
Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-11-30
GEH200520 Injection / GEH200521 (18F) Injection - Part A, GEH200520 Injection / GEH200521
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-03-10
GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-06

Pipeline · 4 trials · 4 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2026-12
Estimated 50%
readout ~2027-01-15
Phase 1/2RegadenosonMyocardial Ischemia, Coronary Artery Disease—recruiting
2027-11-30
Estimated 50%
readout ~2028-02-13
Phase 2/3Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mLKnown or Highly Suspected Central Nervous System (CNS) Lesion, Known or Highly Suspected Body (Excluding CNS) Lesion—recruiting
2029-03-10
Estimated 50%
readout ~2029-04-09
Phase 1GEH200520 Injection / GEH200521 (18F) Injection - Part A, GEH200520 Injection / GEH200521 Malignant Solid Tumor, Oncology—recruiting
2029-06
Estimated 50%
readout ~2029-08-15
Phase 2/3GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT)Colorectal Cancer, Gastric Cancers, Ovarian Cancers, Pancreatic Ductal Adenocarcinoma—recruiting

Catalyst news & presentations · 1

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 454,891,786 · 3 offerings/1y · 0 PIPEs
  • 2026-02-278-Kmaterial_agreement
  • 2025-12-158-Kmaterial_agreement
  • 2025-12-02424B2offering
  • 2025-12-01424B2offering
  • 2025-12-01FWPoffering
  • 2025-06-05424B2offering
  • 2025-06-03424B2offering
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

buy · target $79 (+30% upside) · 18 analysts
  • 2026-07-17Hovde GroupMarket Perform
  • 2026-07-16UBSNeutral
  • 2026-07-09BMO CapitalMarket Perform
  • 2026-06-23RBC CapitalOutperform
  • 2026-05-21UBSSell → Neutral
  • 2026-04-30CitigroupNeutral

Competitors — Colorectal Cancer

  • ABBVAbbVie Inc.$451.1B · D2
  • NVSEFNOVARTIS AG$292.0B · D3
  • RVMDRevolution Medicines, Inc.$40.3B · D1
  • BNTXBioNTech SE$23.1B · D1
  • SMMTSummit Therapeutics Inc.$11.6B · D3
  • IDYAIDEAYA Biosciences, Inc.$3.0B · D3
  • VSTMVerastem, Inc.$515M · D5
  • CRDFCardiff Oncology, Inc.$59M · D3
  • CNTXContext Therapeutics Inc.$57M · D2
  • AZNASTRAZENECA PLC— · D3

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.